Biocon jumps 5% on Japan approval for insulin Glargine

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Biocon gained more than 4 percent intraday Monday on getting approval from the Japan health regulator for insulin.

"Ministry of Health, Labour and Welfare (MHLW) of Japan has approved its biosimilar insulin Glargine," says the company in its filing.

The product is ready-to-use, prefilled disposable pen with 3 ml of 100IU insulin Glargine, expected to be launched in Q1FY17.

Biocon says it targets to capture a significant share of Japanese Glargine market of USD 144 million, which is the second largest market outside of North America & Europe.The company received approval for insulin Glargine after successful completion of initial development and local phase III clinical studies in over 250 type 1 diabetes patients by its partner in Japan. Its commercial partner for this drug is Fujifilm Pharma Co.

At 15:27 hours IST, the scrip of Biocon was quoting at Rs 484.70, up Rs 21.00, or 4.53 percent amid high volumes on the BSE.Posted by Sunil Shankar Matkar